Cylanic 500 mg + 125 mg tablets for dogs

Authorised

- Amoxicillin trihydrate
- Potassium clavulanate

Product identification

Medicine name:
Cylanic 500 mg + 125 mg tablets for dogs
CYLANIC 500 mg + 125 mg, tabletės šunims

Active substance:
Amoxicillin trihydrate
Potassium clavulanate

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Amoxicillin trihydrate
574.03 milligram(s) / 1.00 Tablet
Potassium clavulanate
148.91 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Withdrawal period by route of administration:

Oral use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01CR02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Lithuania

Available in:
Lithuania

Package description:
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 250 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 100 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 50 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 30 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 10 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Industrial Veterinaria S.A.

Marketing authorisation date:
13/06/2021

Manufacturing sites for batch release:
Industrial Veterinaria S.A.
aniMedica Herstellungs GmbH
Lelypharma B.V.
aniMedica GmbH

Responsible authority:
State Food And Veterinary Service

Authorisation number:
LT/2/21/2667/001-005

Date of authorisation status change:
13/06/2021

Reference member state:
Ireland

Procedure number:
IE/V/0582/003

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia Germany Greece Hungary Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

RV2667.pdf
